Nicox SA (OTCPK:NICXF) has initiated
the first Phase 3 clinical trial, named Mont Blanc, evaluating NCX 470
for the lowering of intraocular pressure (IOP) in patients with
open-angle glaucoma or ocular hypertension, by enrolling the first 12
patients.
The Mont Blanc trial will evaluate the efficacy
and safety of NCX 470 ophthalmic solution, 0.065% and 0.1% compared to
latanoprost ophthalmic solution, 0.005%.
The primary efficacy is based on time-matched IOP at 8 AM and 4 PM at Week 2, Week 6 and Month 3.
Adaptive dose selection in Mont Blanc will allow the start of the second Phase 3 trial, Denali.
https://seekingalpha.com/news/3579559-nicox-launches-first-late-stage-ncx-470-trial-in-glaucoma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.